In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.

When insurance denies coverage of cancer treatment, patients with cancer don’t need to take no for an answer, an expert ...

Braftovi received accelerated approval with Erbitux and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

A reflective Christmas morning run, following a cancer diagnosis, inspires profound gratitude for life and a renewed commitment to living a meaningful life.

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the ...

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...